跳转至内容
Merck

SML0965

Sigma-Aldrich

LDN-212854

≥98% (HPLC)

别名:

5-[6-[4-(1-哌嗪基)苯基]吡唑并[1,5-a]嘧啶-3-基]-喹啉

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H22N6
分子量:
406.48
分類程式碼代碼:
51111800
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 1 mg/mL, clear (warmed)

儲存溫度

2-8°C

InChI

1S/C25H22N6/c1-3-21(22-4-2-10-27-24(22)5-1)23-16-29-31-17-19(15-28-25(23)31)18-6-8-20(9-7-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2

InChI 密鑰

BBDGBGOVJPEFBT-UHFFFAOYSA-N

生化/生理作用

LDN-212854 也称为 5- [6- [4-(1-哌嗪基)苯基]吡唑并[1,5-a]嘧啶-3-基]-喹啉。LDN-212854 可防止诱导型突变体 ALK2(激活素受体样激酶 2)中的异位骨化。
LDN-212854 是骨形态发生蛋白(BMP)I 型受体激酶的选择性和有效抑制剂,与密切相关的 TGF-β 和激活素 I 型受体相比,对 BMP 的选择性超过 5,000倍。LDN-212854 对 ALK2 具有某些选择性,IC50 为 1.3 nM,优于其他 BMP I 型受体 ALK1(IC50 = 2.4 nM)和 ALK3(IC50 = 85.8 nM)。 在基于细胞的 BMP 信号试验中,LDN-212854 显示出比 LDN193189 更好的选择性。 LDN-212854 抑制 BMP6 诱导的成骨分化(主要通过 ALK2 起作用),而抑制 BMP4 诱导的分化(主要通过 ALK3 起作用)的效能相对较弱,IC50 分别为 10 nM 和 40.5 nM,而 LDN-193189 两者都抑制。针对 198 种激酶的仅有脱靶效应是针对 RIPK2、ABL1 和 PDGFR-β,IC50 值为 <100 nM。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The Inhibitor Index: A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads (2017)
Hongen Yin et al.
Scientific reports, 10(1), 2967-2967 (2020-02-23)
Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease, with only palliative treatments available. Recent work has suggested that increased bone morphogenetic protein 6 (BMP6) expression could alter cell signaling in the salivary gland (SG) and result in the associated
Huili Zhang et al.
American journal of physiology. Lung cellular and molecular physiology, 313(3), L615-L627 (2017-06-24)
The intracellular signaling mechanisms through which TGF-β regulates pulmonary development are incompletely understood. Canonical TGF-β signaling involves Smad2/3 phosphorylation, Smad2/3·Smad4 complex formation and nuclear localization, and gene regulation. Here, we show that physiologically relevant TGF-β1 levels also stimulate Smad1/5 phosphorylation
Leiming Wang et al.
The Journal of clinical investigation, 130(4), 1782-1792 (2019-12-25)
Recent findings have shown that inhibitors targeting bromodomain and extraterminal domain (BET) proteins, such as the small molecule JQ1, are potent growth inhibitors of many cancers and hold promise for cancer therapy. However, some reports have also revealed that JQ1

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门